Neuroscience

How a popular antidepressant drug could rewire the brain

Prozac, the trade name for the drug fluoxetine, was introduced to the U.S. market for the treatment of depression in 1988. Thirty years later, scientists still don't know exactly how the medication exerts its mood-lifting ...

Neuroscience

Researchers reveal novel therapeutic strategy for ALS

Researchers from the Institute of Neuroscience and their collaborators have revealed a new cellular mechanism for amyotrophic lateral sclerosis (ALS), suggesting a novel therapeutic strategy targeting the RNA degradation ...

Alzheimer's disease & dementia

New compound shows promise in treatment of Alzheimer's

Yale researchers have identified a drinkable cocktail of designer molecules that interferes with a crucial first step of Alzheimer's and even restores memories in mice, they report Jan. 2 in the journal Cell Reports.

Medical research

T-cell biofactories find, fight disease in one fell swoop

NIBIB-funded researchers have transformed T cells into drug factories engineered to find cells carrying specific diseases in the body—and then produce therapeutic proteins localized to the diseased cells.

Parkinson's & Movement disorders

Toward a better understanding of Parkinson's disease

A new study, published today in Nature Structural and Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson's disease.

page 6 from 24